Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-787 and Oseltamivir Interaction and Safety Study
NCT02262715Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pimodivir in Influenza A (IAV) (5 arms), sponsored by Johnson & Johnson. Primary endpoints: Drug-drug interaction between VX-787 and oseltamivir at Day 5, Safety and tolerability of VX-787 and 1 more. Started Jul 2014; status: completed.
02
Drugs
pimodivir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT02262715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262715.